THEOPHYL Drug Patent Profile
✉ Email this page to a colleague
When do Theophyl patents expire, and what generic alternatives are available?
Theophyl is a drug marketed by Ortho Mcneil Pharm, Cent Pharms, Hospira, Inwood Labs, Sandoz, Kv Pharm, Scherer Rp, Alpharma Us Pharms, Cenci, Chartwell Rx, Halsey, Pharm Assoc, Precision Dose, Roxane, Taro, Wockhardt, Chartwell Molecular, Tris Pharma Inc, Able, Alembic, Amneal, Annora Pharma, Bionpharma, Glenmark Pharms Ltd, Harman Finochem, Heritage Pharma Avet, Leading, Nostrum Labs Inc, Rhodes Pharms, Teva Pharms Inc, B Braun, Baxter Hlthcare, and Hospira Inc. and is included in fifty-six NDAs.
The generic ingredient in THEOPHYL is theophylline. There are thirty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theophyl
A generic version of THEOPHYL was approved as theophylline by RHODES PHARMS on September 1st, 1982.
Summary for THEOPHYL
US Patents: | 0 |
Applicants: | 33 |
NDAs: | 56 |
Raw Ingredient (Bulk) Api Vendors: | 171 |
Patent Applications: | 6,960 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for THEOPHYL |
DailyMed Link: | THEOPHYL at DailyMed |